Literature DB >> 12237919

The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

Janet E Olson1, Carol A Janney, Ravi D Rao, James R Cerhan, Paul J Kurtin, David Schiff, Richard S Kaplan, Brian Patrick O'Neill.   

Abstract

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL appears to be increasing.
METHODS: PCNSL incidence data from 1973-1997 were obtained from the nine Surveillance, Epidemiology and End Results (SEER) registries. To limit the influence of the human immunodeficiency virus on incidence rates, data of never-married males and females and persons of unknown marital status were excluded. As a surrogate for new technology, SEER data were reviewed by dates of diagnosis (surrogate for imaging) and compared with glioma incidence (surrogate for stereotactic neurosurgery and improved diagnostic neuropathology). Age-adjusted incidence rates were estimated and compared for the period prior to computed tomography (CT) (1973-1984) and the magnetic resonance imaging (MRI) period (1985-1997). The estimated annual percent change was calculated based on linear regression analyses using SEER*STAT.
RESULTS: The incidence of PCNSL appears to be increasing in all SEER registries examined. All age groups demonstrated an increase over time. This increase was observed both in the CT era as well as in the MRI era. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33% increase) for the same registries over the same time periods. The rate of increase has begun to slow since 1985; the estimated annual percent change for PCNSL was three-fold higher during the period 1973-1985 compared with 1986-1997.
CONCLUSION: The incidence rate of PCNSL continues to rise. The increase is evident in all age groups and in both genders. Data from the current study suggest that improved diagnostic tools, such as CT or MRI, cannot explain this increase. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10851

Entities:  

Mesh:

Year:  2002        PMID: 12237919     DOI: 10.1002/cncr.10851

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  81 in total

1.  IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas.

Authors:  Hema L Ramkumar; De Fen Shen; Jingsheng Tuo; Rita M Braziel; Sarah E Coupland; Justine R Smith; Chi-Chao Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-25       Impact factor: 3.117

Review 2.  Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.

Authors:  N Reddy; B N Savani
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

Review 3.  Diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

4.  Case of Primary Leptomeningeal Lymphoma Presenting with Papilloedema and Characteristics of Pseudotumor Syndrome.

Authors:  Mai Takagi; Hidehiro Oku; Teruyo Kida; Toshikazu Akioka; Tsunehiko Ikeda
Journal:  Neuroophthalmology       Date:  2017-03-23

5.  The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.

Authors:  M C Mabray; R F Barajas; J E Villanueva-Meyer; C A Zhang; F E Valles; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-17       Impact factor: 3.825

6.  Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).

Authors:  Hanne Kuitunen; Susanna Tokola; Topi Siniluoto; Matti Isokangas; Eila Sonkajärvi; Seppo Alahuhta; Taina Turpeenniemi-Hujanen; Esa Jantunen; Tapio Nousiainen; Kaija Vasala; Outi Kuittinen
Journal:  J Neurooncol       Date:  2016-10-17       Impact factor: 4.130

7.  Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Authors:  Elisa J Pulczynski; Outi Kuittinen; Martin Erlanson; Hans Hagberg; Alexander Fosså; Mikael Eriksson; Marie Nordstrøm; Bjørn Østenstad; Øystein Fluge; Sirpa Leppä; Bente Fiirgaard; Hanne Bersvendsen; Unn-Merete Fagerli
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

8.  Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma.

Authors:  Hiroyuki Momota; Yoshitaka Narita; Akiko M Maeshima; Yasuji Miyakita; Aya Shinomiya; Takashi Maruyama; Yoshihiro Muragaki; Soichiro Shibui
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

9.  A case with coincidental diagnosis of primary central nervous system lymphoma and lymph node sarcoidosis.

Authors:  Eva J Greiner; Lars-Olof Mügge; Bernd F M Romeike; Theodoros Topalidis; Bernhard Theis; Andreas Ragoschke-Schumm; Otto W Witte; Albrecht Günther
Journal:  J Neurooncol       Date:  2010-01-07       Impact factor: 4.130

Review 10.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.